The lack of a licensed vaccine for respiratory syncytial virus (RSV) can be partly attributed to
regulatory hurdles resulting from vaccine enhanced respiratory disease (ERD) subsequent …

Respiratory syncytial virus (RSV) is the leading infectious cause of severe respiratory
disease in infants and a major cause of respiratory illness in the elderly. There remains an …

Respiratory syncytial virus (RSV) is estimated to claim more lives among infants< 1 year old
than any other single pathogen, except malaria, and poses a substantial global health …

Respiratory syncytial virus (RSV) has eluded active vaccination efforts for more than five
decades and continues to cause substantial morbidity and mortality in infants, the …

Respiratory syncytial virus causes a significant public health burden, particularly in very
young infants and the frail elderly. The legacy of enhanced RSV disease (ERD) from a …

Human respiratory syncytial virus (RSV) is the leading cause of lower respiratory tract
infections in the very young. The RSV fusion protein (F) is essential for virus entry because it …

Respiratory syncytial virus (RSV) is the leading cause of hospitalization for children under 5
years of age. We sought to engineer a viral antigen that provides greater protection than …

Respiratory syncytial virus (RSV), the main cause of infant bronchiolitis, remains a major
unmet vaccine need despite more than 40 years of vaccine research. Vaccine candidates …

Respiratory syncytial virus (RSV) causes tens of millions of acute lower respiratory tract
infections and millions of hospital admissions globally each year. An antibody repertoire …

Respiratory syncytial virus (RSV) remains a major human pathogen, infecting the majority of
infants before age two and causing re-infection throughout life. Despite decades of RSV …